202 related articles for article (PubMed ID: 11502521)
1. Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy.
Mulheran M; Degg C; Burr S; Morgan DW; Stableforth DE
Antimicrob Agents Chemother; 2001 Sep; 45(9):2502-9. PubMed ID: 11502521
[TBL] [Abstract][Full Text] [Related]
2. Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients.
Mulheran M; Hyman-Taylor P; Tan KH; Lewis S; Stableforth D; Knox A; Smyth A
Antimicrob Agents Chemother; 2006 Jul; 50(7):2293-9. PubMed ID: 16801404
[TBL] [Abstract][Full Text] [Related]
3. No hearing loss after repeated courses of tobramycin in cystic fibrosis patients.
Scheenstra RJ; Heijerman HG; Zuur CL; Touw DJ; Rijntjes E
Acta Otolaryngol; 2010 Feb; 130(2):253-8. PubMed ID: 19479457
[TBL] [Abstract][Full Text] [Related]
4. Aminoglycoside antibiotics cochleotoxicity in paediatric cystic fibrosis (CF) patients: A study using extended high-frequency audiometry and distortion product otoacoustic emissions.
Al-Malky G; Suri R; Dawson SJ; Sirimanna T; Kemp D
Int J Audiol; 2011 Feb; 50(2):112-22. PubMed ID: 21265638
[TBL] [Abstract][Full Text] [Related]
5. Comparison of distortion product OAE generation between a patient group requiring frequent gentamicin therapy and control subjects.
Mulheran M; Degg C
Br J Audiol; 1997 Feb; 31(1):5-9. PubMed ID: 9056039
[TBL] [Abstract][Full Text] [Related]
6. Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation: Ototoxicity following tobramycin treatment.
Harruff EE; Kil J; Ortiz MGT; Dorgan D; Jain R; Poth EA; Fifer RC; Kim YJM; Shoup AG; Flume PA
J Cyst Fibros; 2021 Mar; 20(2):288-294. PubMed ID: 33341407
[TBL] [Abstract][Full Text] [Related]
7. Incidence of nephrotoxicity with prolonged aminoglycoside exposure in patients with cystic fibrosis.
Saad A; Young MR; Studtmann AE; Autry EB; Schadler A; Beckman EJ; Gardner BM; Wurth MA; Kuhn RJ
Pediatr Pulmonol; 2020 Dec; 55(12):3384-3390. PubMed ID: 32910553
[TBL] [Abstract][Full Text] [Related]
8. Otoacoustic emissions for monitoring aminoglycoside-induced ototoxicity in children with cystic fibrosis.
Stavroulaki P; Vossinakis IC; Dinopoulou D; Doudounakis S; Adamopoulos G; Apostolopoulos N
Arch Otolaryngol Head Neck Surg; 2002 Feb; 128(2):150-5. PubMed ID: 11843723
[TBL] [Abstract][Full Text] [Related]
9. Prospective cohort study of ototoxicity in persons with cystic fibrosis following a single course of intravenous tobramycin.
Garinis A; Gleser M; Johns A; Larsen E; Vachhani J
J Cyst Fibros; 2021 Mar; 20(2):278-283. PubMed ID: 32713806
[TBL] [Abstract][Full Text] [Related]
10. Exploring the Relationship between FEV
Hoff BM; Scheetz MH; Jain M; Cullina JF; Rhodes NJ
Pharmacotherapy; 2020 Jun; 40(6):584-591. PubMed ID: 32259317
[TBL] [Abstract][Full Text] [Related]
11. High-frequency audiometry reveals high prevalence of aminoglycoside ototoxicity in children with cystic fibrosis.
Al-Malky G; Dawson SJ; Sirimanna T; Bagkeris E; Suri R
J Cyst Fibros; 2015 Mar; 14(2):248-54. PubMed ID: 25127922
[TBL] [Abstract][Full Text] [Related]
12. Aminoglycoside ototoxicity in cystic fibrosis. Evaluation by high-frequency audiometry.
McRorie TI; Bosso J; Randolph L
Am J Dis Child; 1989 Nov; 143(11):1328-32. PubMed ID: 2816859
[TBL] [Abstract][Full Text] [Related]
13. A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs.
Prescott WA
Respir Care; 2014 Sep; 59(9):1353-9. PubMed ID: 24782555
[TBL] [Abstract][Full Text] [Related]
14. Piperacillin-tazobactam versus cefepime incidence of acute kidney injury in combination with vancomycin and tobramycin in pediatric cystic fibrosis patients.
LeCleir LK; Pettit RS
Pediatr Pulmonol; 2017 Aug; 52(8):1000-1005. PubMed ID: 28440913
[TBL] [Abstract][Full Text] [Related]
15. High frequency hearing thresholds and product distortion otoacoustic emissions in cystic fibrosis patients.
Geyer LB; Menna Barreto SS; Weigert LL; Teixeira AR
Braz J Otorhinolaryngol; 2015; 81(6):589-97. PubMed ID: 26480907
[TBL] [Abstract][Full Text] [Related]
16. Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity.
Prayle A; Smyth AR
Curr Opin Pulm Med; 2010 Nov; 16(6):604-10. PubMed ID: 20814306
[TBL] [Abstract][Full Text] [Related]
17. The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis.
Garinis AC; Cross CP; Srikanth P; Carroll K; Feeney MP; Keefe DH; Hunter LL; Putterman DB; Cohen DM; Gold JA; Steyger PS
J Cyst Fibros; 2017 May; 16(3):401-409. PubMed ID: 28238634
[TBL] [Abstract][Full Text] [Related]
18. Intravenous injection of gentamicin and tobramycin without impairment of hearing.
Dobbs SM; Mawer GE
J Infect Dis; 1976 Aug; 134 Suppl():S114-7. PubMed ID: 972268
[TBL] [Abstract][Full Text] [Related]
19. Chirp-Evoked Otoacoustic Emissions and Middle Ear Absorbance for Monitoring Ototoxicity in Cystic Fibrosis Patients.
Garinis AC; Keefe DH; Hunter LL; Fitzpatrick DF; Putterman DB; McMillan GP; Gold JA; Feeney MP
Ear Hear; 2018; 39(1):69-84. PubMed ID: 28708814
[TBL] [Abstract][Full Text] [Related]
20. Influence of multiple courses of therapy on aminoglycoside clearance in adult patients with cystic fibrosis.
Alghanem S; Paterson I; Touw DJ; Thomson AH
J Antimicrob Chemother; 2013 Jun; 68(6):1338-47. PubMed ID: 23435691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
